IN8bio Announces Structured $40 Million Private Placement Financing

IN8bio ( (INAB) ) has issued an announcement.

On December 18, 2025, IN8bio, Inc. entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants in two potential tranches, aiming to raise approximately $40.2 million in gross proceeds before fees if both closings occur. The initial closing, expected on or about December 22, 2025, will provide about $20.1 million through the sale of 5,127,029 shares at $1.38 per share and pre-funded warrants for 9,452,677 shares at $1.3799 each, while a second $20.1 million tranche is contingent on achieving specified development and share-price milestones tied to its INB-619 product candidate or an investor waiver, with investors also receiving registration rights for resale and participation rights in future equity financings, underscoring a structured approach to funding that links additional capital to clinical progress and market performance.

The most recent analyst rating on (INAB) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.

Spark’s Take on INAB Stock

According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.

IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.

To see Spark’s full report on INAB stock, click here.

More about IN8bio

Average Trading Volume: 69,686

Technical Sentiment Signal: Sell

Current Market Cap: $6.58M

See more data about INAB stock on TipRanks’ Stock Analysis page.